Species trait selection along a prescribed fire chronosequence

1. Fire is a widespread management practice used in the maintenance of European heathland. Frequent prescribed burns in small patches have been shown to benefit carabid communities; however, how fire favours specific life-history traits is poorly understood. 2. In this study, we identify characteristic species of the successional stages within heathlands, and find the traits which are characteristic of species in burnt areas versus areas dominated by older heath stands. 3. We identify 10 species as indicator species for heathland in the pioneer stage (0–5 years old); Amara lunicollis, Bembidion lampros, Calathus fuscipes, Carabus problematicus, Cicindela campestris, Nebria salina, Notiophilus aquaticus, Poecilus cupreus, P. lepidus and P. versicolor. Dyschirius globosus is identified as an indicator for the building stage (6–14 years old), and Carabus violaceus as an indicator for the mature stage (15–25 years old). 4. Moisture preference and diet are identified as traits that determine species response to prescribed fire. Collembolan specialists and species with no moisture preference are shown to be most abundant in burnt patches, whereas generalist predators and species with a high moisture preference are less tolerant of fire. 5. Knowledge of species sorting along a prescribed fire gradient can provide valuable information for heathland conservation.publishedVersio

Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial

Objectives Many patients with rheumatoid arthritis (RA) require treatment with tumour necrosis factor inhibitor (TNFi) to reach remission. It is debated whether tapering of TNFi to discontinuation should be considered in sustained remission. The aim of ARCTIC REWIND TNFi was to assess the effect of tapering TNFi to withdrawal compared with stable treatment on the risk of disease activity flares in patients with RA in remission ≥1 year.Methods This randomised, open-label, non-inferiority trial was undertaken at nine Norwegian rheumatology departments. Patients with RA in remission ≥12 months on stable TNFi therapy were allocated by computer-based block-randomisation to tapering to discontinuation of TNFi or stable TNFi. Conventional synthetic disease-modifying antirheumatic co-medication was unchanged. The primary endpoint was disease flare during the 12-month study period (non-inferiority margin 20%), assessed in the per-protocol population.Results Between June 2013 and January 2019, 99 patients were enrolled and 92 received the allocated treatment strategy. Eighty-four patients were included in the per-protocol population. In the tapering TNFi group, 27/43 (63%) experienced a flare during 12 months, compared with 2/41 (5%) in the stable TNFi group; risk difference (95% CI) 58% (42% to 74%). The tapering strategy was not non-inferior to continued stable treatment. The number of total/serious adverse events was 49/3 in the tapering group, 57/2 in the stable group.Conclusion In patients with RA in remission for more than 1 year while using TNFi, an increase in flare rate was reported in those who tapered TNFi to discontinuation. However, most regained remission after reinstatement of full-dose treatment.Pathophysiology and treatment of rheumatic disease

Effect of half-dose vs stable-dose conventional synthetic disease-modifying antirheumatic drugs on disease flares in patients with rheumatoid arthritis in remission: the ARCTIC REWIND randomized clinical trial

This randomized trial compares the effects of half-dose conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) vs stable-dose csDMARDs on the risk of flares in patients with rheumatoid arthritis in sustained remission.Importance Sustained remission has become an achievable goal for patients with rheumatoid arthritis (RA) receiving conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), but how to best treat patients in clinical remission remains unclear. Objective To assess the effect of tapering of csDMARDs, compared with continuing csDMARDs without tapering, on the risk of flares in patients with RA in sustained remission. Design, Setting, and Participants ARCTIC REWIND was a multicenter, randomized, parallel, open-label noninferiority study conducted in 10 Norwegian hospital-based rheumatology practices. A total of 160 patients with RA in remission for 12 months who were receiving stable csDMARD therapy were enrolled between June 2013 and June 2018, and the final visit occurred in June 2019. Interventions Patients were randomly assigned to half-dose csDMARDs (n = 80) or stable-dose csDMARDs (n = 80). Main Outcomes and Measures The primary end point was the proportion of patients with a disease flare between baseline and the 12-month follow-up, defined as a combination of Disease Activity Score (DAS) greater than 1.6 (threshold for RA remission), an increase in DAS score of 0.6 units or more, and at least 2 swollen joints. A disease flare could also be recorded if both the patient and investigator agreed that a clinically significant flare had occurred. A risk difference of 20% was defined as the noninferiority margin. Results Of 160 enrolled patients (mean [SD] age, 55.1 [11.9] years; 66% female), 156 received the allocated therapy, of which 155 without any major protocol violations were included in the primary analysis population (77 receiving half-dose and 78 receiving stable-dose csDMARDs). Flare occurred in 19 patients (25%) in the half-dose csDMARD group compared with 5 (6%) in the stable-dose csDMARD group (risk difference, 18% [95% CI, 7%-29%]). Adverse events occurred in 34 patients (44%) in the half-dose group and 42 (54%) in the stable-dose group, none leading to study discontinuation. No deaths occurred. Conclusions and Relevance Among patients with RA in remission taking csDMARD therapy, treatment with half-dose vs stable-dose csDMARDs did not demonstrate noninferiority for the percentage of patients with disease flares over 12 months, and there were significantly fewer flares in the stable-dose group. These findings do not support treatment with half-dose therapy.Question In patients with rheumatoid arthritis in remission taking conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), is reducing the csDMARDs to half dose noninferior to stable csDMARD dosage for the outcome of rheumatoid arthritis flares? Findings In this randomized clinical trial that included 160 patients with rheumatoid arthritis in remission taking csDMARD therapy, treatment with half-dose vs stable-dose csDMARDs resulted in disease flares in 25% vs 6% over 12 months; this did not meet the noninferiority criterion of a 20% difference. There were significantly fewer patients with flares in the stable-dose group. Meaning These findings do not support the use of half-dose treatment in patients with rheumatoid arthritis in remission taking csDMARDs.Pathophysiology and treatment of rheumatic disease

Scandinavian society for the study of diabetes Abstracts Seventh Meeting

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/46039/1/125_2005_Article_BF01219478.pd

Boom and bust of a moose population – a call for integrated forest management

This is the postprint version of the article. The published article can be located at www.springerlink.comThere is increasing pressure to manage forests for multiple objectives, including ecosystem services and biodiversity, alongside timber production. However, few forests are currently co-managed for timber and wildlife, despite potential economic and conservation benefits. We present empirical data from a commercial Norway spruce ( Picea abies ) and Scots pine ( Pinus sylvestris ) production system in southern Norway in which moose ( Alces alces ) are an important secondary product. Combining long-term hunting and forestry records, we identified temporal vari- ation in clear-felling over the past five decades, peaking in the 1970s. Herbicide treatment of regenerating stands and a fivefold increase in moose harvest has lead to a reduction in availability of successional forest per moose of [ 90 % since the 1960s. Field estimates showed that spraying with the herbicide glyphosate reduced forage availability by 60 and 96 % in summer and winter, respectively, 4 years after treatment. It also reduced moose use and habitat selection of young spruce stands compared with unsprayed stands. Together these lines of evidence suggest that forest man- agement led to an increase in moose carrying capacity during the 1970s and a subsequent decline thereafter. This is likely to have contributed to observed reductions in moose population productivity in southern Norway and is counter to sustainable resource management. We therefore call for better integration and long-term planning between forestry and wildlife management to minimise forest damage and the development of large fluctuations in ungulate populations

Er samspill fremtiden i offentlige byggeprosjekt?

Denne rapporten handler om samspillsentreprise og hvordan det blir brukt i offentlige byggeprosjekt. En entreprise er en strukturert avtale mellom byggherre og entreprenør. Denne organiserer prosjektgjennomføring, fordeler ansvar og regulerer de kommersielle forholdene mellom partene. Til nå har totalentrepriser vært den dominerende entrepriseformen, men ved mer komplekse prosjekter hvor det er behov for tettetere samarbeid, er det utviklet nye entrepriseformer. Samspillsentreprise er en forholdsvis ny entrepriseform, som blir stadig mer brukt i offentlige prosjekt. Den kjennetegnes ved at det blir benyttet et tettere samarbeid mellom aktørene i prosjektet, og dermed får bedre utnyttet kompetansen i teamet, tverrfaglig. I dette ligger også god tilrettelegging for å avdekke endringsbehov allerede i en tidligfase, hvor konsekvensene og endringskostnadene er små. Per dags dato er ikke samspillsentreprise en standardisert entrepriseform, noe som gjør det vanskelig å vite hvordan samspill skal gjennomføres, eller om det vil gi positive resultater. Dette behovet har utløst denne BSc-oppgaven, hvor vi går inn i konkrete prosjekter og analyserer utfallet. Rapporten baseres på en kombinasjon av prosjektstudie og intervju. Prosjektstudiet består av fire skolebyggeprosjekter i Molde, Ålesund og Oslo, hvor tilhørende fylkeskommuner er offentlige byggherrer. Det undersøkes hvordan prosjektene har organisert og gjennomført samspillet i ulike prosjektfaser. Dette er koblet opp mot lønnsomhetsanalyser, for å vurdere effekten av Samspillsentreprisen. Studien tar utgangspunkt i et eksplorativt forskningsdesign, og baseres på en triangulær innsamlingsmetode med data fra tilhørende prosjektdokument og semistrukturerte dybdeintervju. Resultatet av analysene viste at alle prosjektene hadde en mer effektiv og forutsigbar planlegging pga. den tverrfaglige kommunikasjonen som samspill legger opp til. Det kom også fram at behovet for samspill økter i takt med prosjektets kompleksitet, med stor påvirkning på prosjektets framdrift og økonomi. Samspillentreprisen vurderes derfor som en tids- og kostnadseffektiv entrepriseform, men trenger samtidig å videreutvikles for å få ut det fulle potensialet. Rapporten konkluderer derfor med at konseptet samspill er lønnsomt dersom de rette forutsetningene ligger til grunn